Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD)

Overview

Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD) is a rare but serious condition that occurs when the live virus in the yellow fever vaccine causes a disease similar to wild-type yellow fever. This condition is extremely uncommon, with an estimated incidence of 0.3 to 0.4 cases per 100,000 vaccine doses (CDC, 2021).

YEL-AVD primarily affects individuals who have received the yellow fever vaccine, particularly those who are older adults (over 60 years) or have weakened immune systems. The condition mimics severe yellow fever, affecting multiple organs, including the liver, kidneys, and heart.

While yellow fever vaccination is crucial for travelers to endemic regions, understanding YEL-AVD helps in recognizing its symptoms early and seeking prompt medical care.

Symptoms

Symptoms of YEL-AVD typically appear 2 to 5 days after vaccination and may include:

• High fever (often above 101°F or 38.3°C)
• Severe headache
• Muscle and joint pain
• Fatigue and weakness
• Nausea and vomiting
• Jaundice (yellowing of the skin and eyes due to liver dysfunction)
• Abdominal pain
• Bleeding or bruising easily (due to liver impairment)
• Low blood pressure (hypotension)
• Organ failure (in severe cases, affecting the liver, kidneys, or heart)

These symptoms can progress rapidly, making early recognition critical.

Causes and Risk Factors

YEL-AVD is caused by the live attenuated (weakened) virus in the yellow fever vaccine. While the vaccine is generally safe, in rare cases, the virus can replicate uncontrollably, leading to viscerotropic disease (affecting internal organs).

Risk Factors

• Age over 60: The risk increases significantly with age, particularly in those over 70.
• Weakened immune system: Due to conditions like HIV/AIDS, cancer, or immunosuppressive therapies.
• Thymus disorders: Such as thymoma or myasthenia gravis.
• First-time vaccination: Those receiving the vaccine for the first time may have a slightly higher risk.

According to the CDC, the risk of YEL-AVD is higher in older adults, with 80% of reported cases occurring in individuals over 60.

Diagnosis

Diagnosing YEL-AVD involves a combination of clinical evaluation and laboratory tests:

• Medical history review: Including recent vaccination status.
• Physical examination: Checking for jaundice, fever, and organ dysfunction.
• Blood tests:
  • Liver function tests (elevated liver enzymes)
  • Complete blood count (CBC)
  • Viral RNA detection (PCR testing for yellow fever virus)
• Imaging studies: Such as ultrasounds or CT scans to assess organ damage.

Early diagnosis is crucial for managing symptoms and preventing complications.

Treatment Options

There is no specific antiviral treatment for YEL-AVD. Management focuses on supportive care to stabilize the patient:

• Hospitalization: Often in an intensive care unit (ICU) for severe cases.
• Intravenous (IV) fluids: To maintain hydration and blood pressure.
• Medications:
  • Pain relievers (e.g., acetaminophen)
  • Antiemetics for nausea
  • Blood pressure support (vasopressors if needed)
• Liver support: Including monitoring for liver failure.
• Blood transfusions: If bleeding occurs due to liver dysfunction.

Recovery depends on the severity of organ involvement and timely medical intervention.

Living with Yellow Fever Vaccine-Associated Viscerotropic Disease

For those recovering from YEL-AVD, long-term management may include:

• Regular follow-up appointments with a healthcare provider.
• Monitoring liver and kidney function through blood tests.
• Gradual return to normal activities as strength improves.
• Avoiding alcohol and liver-toxic medications to protect liver health.
• Staying hydrated and eating a balanced diet to support recovery.

Most survivors recover fully, but some may experience lingering fatigue or organ dysfunction.

Prevention

Preventing YEL-AVD involves careful consideration of vaccination risks:

• Assess vaccination necessity: Only get vaccinated if traveling to a yellow fever-endemic area.
• Discuss risks with a healthcare provider, especially if over 60 or immunocompromised.
• Consider alternative protections (e.g., mosquito avoidance) if vaccination is high-risk.
• Follow CDC or WHO guidelines for yellow fever vaccination recommendations.

The yellow fever vaccine remains highly effective and safe for most people, but weighing risks is essential for high-risk individuals.

Complications

If untreated, YEL-AVD can lead to severe complications, including:

• Liver failure
• Kidney failure
• Septic shock
• Death (in approximately 50% of cases, per NIH data)

Early medical intervention significantly improves outcomes.

When to Seek Emergency Care